Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
12
datasets available to search
ShareScore release 0.9.0
Dataset results
12 results for “total marrow and lymphoid irradiation”
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ClinicalTrials.gov study NCT02094794. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia
ClinicalTrials.gov study NCT03408223. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
ClinicalTrials.gov study NCT03408210. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov study NCT06195891. IPD Sharing: Not stated. Countries: 1. Publications: 0.
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With Hig
ClinicalTrials.gov study NCT06287944. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
ClinicalTrials.gov study NCT04262843. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov study NCT03494569. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
ClinicalTrials.gov study NCT03467386. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
ClinicalTrials.gov study NCT02446964. IPD Sharing: Not stated. Countries: 1. Publications: 0.
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov study NCT05139004. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dataset related to article "Evaluation of plan complexity and dosimetric plan quality of total marrow and lymphoid irradiation using volumetric modulated arc therapy"
<p>This record contains raw data related to article "Evaluation of plan complexity and dosimetric plan quality of total marrow and lymphoid irradiation using volumetric modulated arc therapy"</p><p> Abstract</p><p>Purpose: To assess the impact of the planner's experience and optimization algorithm on the plan quality and complexity of total marrow and lymphoid irradiation (TMLI) delivered by means of volumetric modulated arc therapy (VMAT) over 2010-2022 at our institute.</p><p>Methods: Eighty-two consecutive TMLI plans were considered. Three complexity indices were computed to characterize the plans in terms of leaf gap size, irregularity of beam apertures, and modulation complexity. Dosimetric points of the target volume (D2%) and organs at risk (OAR) (Dmean) were automatically extracted to combine them with plan complexity and obtain a global quality score (GQS). The analysis was stratified based on the different optimization algorithms used over the years, including a knowledge-based (KB) model. Patient-specific quality assurance (QA) using Portal Dosimetry was performed retrospectively, and the gamma agreement index (GAI) was investigated in conjunction with plan complexity.</p><p>Results: Plan complexity significantly reduced over the years (r = -0.50, p < 0.01). Significant differences in plan complexity and plan dosimetric quality among the different algorithms were observed. Moreover, the KB model allowed to achieve significantly better dosimetric results to the OARs. The plan quality remained similar or even improved during the years and when moving to a newer algorithm, with GQS increasing from 0.019 ± 0.002 to 0.025 ± 0.003 (p < 0.01). The significant correlation between GQS and time (r = 0.33, p = 0.01) indicated that the planner's experience was relevant to improve the plan quality of TMLI plans. Significant correlations between the GAI and the complexity metrics (r = -0.71, p < 0.01) were also found.</p><p>Conclusion: Both the planner's experience and algorithm version are crucial to achieve an optimal plan quality in TMLI plans. Thus, the impact of the optimization algorithm should be carefully evaluated when a new algorithm is introduced and in system upgrades. Knowledge-based strategies can be useful to increase standardization and improve plan quality of TMLI treatments</p>
Dataset related to article "Deep learning and atlas-based models to streamline the segmentation workflow of Total Marrow and Lymphoid Irradiation"
<p>This record contains raw data related to article “Deep learning and atlas-based models to streamline the segmentation workflow of Total Marrow and Lymphoid Irradiation"</p> <p>Abstract:</p> <p><strong>Purpose: </strong>To improve the workflow of Total Marrow and Lymphoid Irradiation (TMLI) by enhancing the delineation of organs-at-risk (OARs) and clinical target volume (CTV) using deep learning (DL) and atlas-based (AB) segmentation models.</p> <p><strong>Materials and Methods:</strong> Ninety-five TMLI plans optimized in our institute were analyzed. Two commercial DL software were tested for segmenting 18 OARs. An AB model for lymph node CTV (CTV_LN) delineation was built using 20 TMLI patients. The AB model was evaluated on 20 independent patients and a semi-automatic approach was tested by correcting the automatic contours. The generated OARs and CTV_LN contours were compared to manual contours in terms of topological agreement, dose statistics, and time workload. A clinical decision tree was developed to define a specific contouring strategy for each OAR.</p> <p><strong>Results: </strong>The two DL models achieved a median Dice Similarity Coefficient (DSC) of 0.84 [0.73;0.92] and 0.84 [0.77;0.93] across the OARs. The absolute median dose (Dmedian) difference between manual and the two DL models was 2% [1%;5%] and 1% [0.2%;1%]. The AB model achieved a median DSC of 0.70 [0.66;0.74] for CTV_LN delineation, increasing to 0.94 [0.94;0.95] after manual revision, with minimal Dmedian differences. Since September 2022, our institution has implemented DL and AB models for all TMLI patients, reducing from 5 to 2 hours the time required to complete the entire segmentation process.</p> <p><strong>Conclusion: </strong>DL models can streamline the TMLI contouring process of OARs. Manual revision is still necessary for lymph node delineation using AB models.</p> <p> </p> <p><strong>Statements & Declarations</strong></p> <p><strong>Funding:</strong> This work was funded by the Italian Ministry of Health, grant AuToMI (GR-2019-12370739).</p> <p><strong>Competing Interests:</strong> The authors have no conflict of interests to disclose.</p> <p><strong>Author Contributions:</strong> All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by D.D., N.L., L.C., R.C.B., D.L., and P.M. The first draft of the manuscript was written by D.D. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p> <p><strong>Ethics approval:</strong> The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of IRCCS Humanitas Research Hospital (ID 2928, 26 January 2021). ClinicalTrials.gov identifier: NCT04976205.</p> <p><strong>Consent to participate: </strong>Informed consent was obtained from all individual participants included in the study.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.